@article{ART001612489,
author={신형찬 and 배영경 and 김애리 and 박석주},
title={HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing},
journal={Journal of Pathology and Translational Medicine},
issn={2383-7837},
year={2011},
volume={45},
number={6},
pages={665-669}
}

TY - JOUR
AU - 신형찬
AU - 배영경
AU - 김애리
AU - 박석주
TI - HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing
T2 - Journal of Pathology and Translational Medicine
JO - Journal of Pathology and Translational Medicine
PY - 2011
VL - 45
IS - 6
PB - 대한병리학회
SP - 665
EP - 669
SN - 2383-7837
AB - Recently we experienced three cases of human epidermal growth factor receptor 2 (HER2)-amplified invasive breast carcinomas associated with co-amplification or gain of chromosome 17 centromere (CEP17) in silver-enhanced in situ hybridization (SISH) analysis. These cases revealed 2+ or 3+ staining for HER2 immunohistochemistry and >6 HER2 copies per cell on SISH analyses. However, the calculated HER2/CEP17 ratios were low (<2.2) and did not fit within the HER2-positive category. We interpreted those cases as HER2-positive tumors based on the number of HER2 copies per cell. There is a potential for misinterpretation of SISH analysis in cases showing increased CEP17 copy number, based on the criterion used for HER2 positivity (HER2 copies >6 per cell vs HER2/CEP17 ratio>2.2). We recommend reporting raw SISH or fluorescence in situ hybridization data, including number of cells counted, average numbers of HER2 and CEP17 signals, and the calculated HER2/CEP17 ratio to prevent underreporting of HER2 amplification.
KW - Breast neoplasms, HER2; Amplification, Chromosome 17, Polysomy
DO -
UR -
ER -

신형찬, 배영경, 김애리 and 박석주. 2011, "HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing", Journal of Pathology and Translational Medicine, vol.45, no.6 pp.665-669.

신형찬, 배영경, 김애리, 박석주 "HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing" Journal of Pathology and Translational Medicine 45.6 pp.665-669 (2011) : 665.

신형찬, 배영경, 김애리, 박석주. HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing. 2011; 45(6), 665-669.

신형찬, 배영경, 김애리 and 박석주. "HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing" Journal of Pathology and Translational Medicine 45, no.6 (2011) : 665-669.

신형찬; 배영경; 김애리; 박석주. HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing. Journal of Pathology and Translational Medicine, 45(6), 665-669.

신형찬; 배영경; 김애리; 박석주. HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing. Journal of Pathology and Translational Medicine. 2011; 45(6) 665-669.

신형찬, 배영경, 김애리, 박석주. HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing. 2011; 45(6), 665-669.

신형찬, 배영경, 김애리 and 박석주. "HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing" Journal of Pathology and Translational Medicine 45, no.6 (2011) : 665-669.